DENTSPLY SIRONA (XRAY) Projected to Announce Earnings on Thursday

DENTSPLY SIRONA (NASDAQ:XRAY) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.3480 per share and revenue of $889.9280 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. DENTSPLY SIRONA’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.43 earnings per share. On average, analysts expect DENTSPLY SIRONA to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $14.27 on Wednesday. The stock’s 50-day simple moving average is $11.61 and its 200 day simple moving average is $11.87. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -4.53, a price-to-earnings-growth ratio of 1.68 and a beta of 0.85. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA has a 52-week low of $9.40 and a 52-week high of $14.86.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. UBS Group lowered their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Barclays decreased their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. Piper Sandler increased their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. BMO Capital Markets began coverage on shares of DENTSPLY SIRONA in a report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price target for the company. Finally, Mizuho reduced their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $13.46.

Insider Buying and Selling

In other news, Director Brian T. Gladden purchased 9,985 shares of the company’s stock in a transaction on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This trade represents a 19.25% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Barber acquired 15,175 shares of DENTSPLY SIRONA stock in a transaction dated Thursday, June 11th. The shares were purchased at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director directly owned 55,943 shares in the company, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 35,160 shares of company stock worth $351,179. Corporate insiders own 0.46% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. lifted its holdings in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in shares of DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.